(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

USOS DE VALBENAZINA

Em AnáliseInvention PatentPCT · US2022073209

Application data

Invention Patent USOS DE VALBENAZINA de NEUROCRINE BIOSCIENCES INC. — IPC A61K 31/4745
Invention Patent USOS DE VALBENAZINA de NEUROCRINE BIOSCIENCES INC. — IPC A61K 31/4745. Drawing published by the INPI in the Industrial Property Gazette.

Number

112023026691

Type

Invention Patent

Filing

06/28/2022

Publication

03/05/2024

PCT

US2022073209

Progress at the INPI

  1. Filing06/28/22
  2. Publication
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The application was filed at the INPI on 06/28/2022. It awaits formal examination and publication in the RPI gazette.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 02/10/2026. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

NEUROCRINE BIOSCIENCES INC.

US

See this company's full portfolio

Inventors

A. A. (pessoa física)

US

Technical data

Priority claims

US

63/216,875 · 06/30/2021

US

63/242,794 · 09/10/2021

US

63/276,079 · 11/05/2021

US

63/362,561 · 04/06/2022

Abstract

VALBENAZINA PARA USO NO TRATAMENTO COMPLEMENTAR DE ESQUIZOFRENIA. A presente invenção refere-se a métodos para o tratamento complementar de esquizofrenia usando um inibidor de isoforma transportadora de monoamina vesicular 2 (VMAT2). Em certas modalidades, o inibidor de VMAT2 é valbenazina ou um sal farmaceuticamente aceitável do mesmo.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Alteração de sede deferida

#25.7

02/10/2026

RPI 2875

Notificação de entrada na fase nacional - PCT

#1.3

03/05/2024

RPI 2774

Alteração de dados cadastrais

#1.1

12/26/2023

RPI 2764

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.